Search

Graph-based learning approaches, due to their ability to encode tissue/organ structure information, are increasingly favored for grading colorectal cancer histology images. Recent graph-based techniques involve dividing whole slide images (WSIs) into smaller or medium-sized patches, and then building graphs on each patch for direct use in training. This method, however, fails to capture the tissue structure information present in an entire WSI and relies on training from a significantly large dataset of image patches. In this paper, we propose a novel cell-to-patch graph convolutional network (C2P-GCN), which is a two-stage graph formation-based approach. In the first stage, it forms a patch-level graph based on the cell organization on each patch of a WSI. In the second stage, it forms an image-level graph based on a similarity measure between patches of a WSI considering each patch as a node of a graph. This graph representation is then fed into a multi-layer GCN-based classification network. Our approach, through its dual-phase graph construction, effectively gathers local structural details from individual patches and establishes a meaningful connection among all patches across a WSI. As C2P-GCN integrates the structural data of an entire WSI into a single graph, it allows our model to work with significantly fewer training data compared to the latest models for colorectal cancer. Experimental validation of C2P-GCN on two distinct colorectal cancer datasets demonstrates the effectiveness of our method., Comment: Accepted at IEEE EMBC 2024

Vascular normalization therapy has the potential to facilitate drug delivery and lymphocyte infiltration in tumors. Yet, optimal targets and dosage regimens remain elusive. In this issue of Med, O’Connor et al. show that inhibition of LRG1 stabilizes the tumor-associated vasculature to enhance tumor response to both cytotoxic and immune therapies.

There is a lack of appropriate melanoma models that can be used to evaluate the efficacy of novel therapeutic modalities. Here, we discuss the current state of the art of melanoma models including genetically engineered mouse, patient-derived xenograft, zebrafish, and ex vivo and in vitro models. We also identify five major challenges that can be addressed using such models, including metastasis and tumor dormancy, drug resistance, the melanoma immune response, and the impact of aging and environmental exposures on melanoma progression and drug resistance. Additionally, we discuss the opportunity for building models for rare subtypes of melanomas, which represent an unmet critical need. Finally, we identify key recommendations for melanoma models that may improve accuracy of preclinical testing and predict efficacy in clinical trials, to help usher in the next generation of melanoma therapies.

Vascular normalization therapy has the potential to facilitate drug delivery and lymphocyte infiltration in tumors. Yet, optimal targets and dosage regimens remain elusive. In this issue of Med, O’Connor et al. show that inhibition of LRG1 stabilizes the tumor-associated vasculature to enhance tumor response to both cytotoxic and immune therapies.